Longer follow-up presented at the 2026 ESMO Congress showed that four already-approved treatments for early breast cancer, kidney cancer, colorectal cancer and stomach and esophageal cancer kept helping patients years later.
|Articles|April 19, 2020
Stay Connected During COVID-19
Author(s)Susan G. Komen NYC
Stay connected during these challenging times and keep up with all the news and updates from Susan G. Kommen Greater NYC by signing up for our latest newsletter!
Advertisement
Susan G. Komen Greater NYC is dedicated to connecting with our community during this challenging period of isolation. We are providing a weekly newsletter filled with virtual resources, new developments, events, articles, and valuable information that keeps our community members linked and up to date!
Sign up for the newsletter
Advertisement
Related to this article
Two phase 3 trials at ESMO 2026 brought new options for advanced endometrial cancer, and final results for Verzenio after another CDK4/6 drug showed a survival difference that was not statistically significant.
An expert at ESMO 2026 explains how liquid biopsy and ESR1 testing can help guide treatment for people with HR-positive metastatic breast cancer.
Martha Carlson reflects on her 11 years with metastatic breast cancer and explores how resilience, purpose and the stories we tell ourselves shape the cancer experience.
A study found that 1 in 9 older cancer survivors developed a second cancer, highlighting why routine screening remains important beyond five years.
After breast cancer at 30, Aisha shares her journey through motherhood, a double mastectomy, body image struggles and the challenges of survivorship.
A study found that sentinel lymph node biopsy rarely missed remaining cancer in patients with locally advanced breast cancer whose lymph nodes responded to chemotherapy before surgery.
Lower income, later diagnosis and gaps in treatment drove most of the excess deaths among rural patients, according to new research.
Advertisement
Advertisement
Trending on CURE
1
4 Long-Term Survival Results From ESMO 2026 Patients Should Know
2
Top 5 Takeaways From ESMO 2026 That Patients Should Know
3
Neuro-Oncologist Answers Common Questions About Brain Cancer Diagnosis and Treatment
4
Cancer Caregivers Had 89% Higher Odds of Frequent Mental Distress
5